IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
0.1715
-0.0246 (-12.54%)
Mar 31, 2025, 2:31 PM EDT - Market open
IN8bio Employees
IN8bio had 18 employees as of December 31, 2024. The number of employees decreased by 13 or -41.94% compared to the previous year.
Employees
18
Change (1Y)
-13
Growth (1Y)
-41.94%
Revenue / Employee
n/a
Profits / Employee
-$1,690,944
Market Cap
13.94M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18 | -13 | -41.94% |
| Dec 31, 2023 | 31 | 5 | 19.23% |
| Dec 31, 2022 | 26 | 7 | 36.84% |
| Dec 31, 2021 | 19 | 5 | 35.71% |
| Dec 31, 2020 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INAB News
- 6 hours ago - IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025 - GlobeNewsWire
- 13 days ago - IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025 - GlobeNewsWire
- 17 days ago - IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 weeks ago - IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases - GlobeNewsWire
- 4 weeks ago - IN8bio to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 5 weeks ago - IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewsWire
- 6 weeks ago - IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML - GlobeNewsWire
- 6 weeks ago - IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients - GlobeNewsWire